Cargando…
Recombinant pharmaceuticals from microbial cells: a 2015 update
Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748523/ https://www.ncbi.nlm.nih.gov/pubmed/26861699 http://dx.doi.org/10.1186/s12934-016-0437-3 |
_version_ | 1782415133202448384 |
---|---|
author | Sanchez-Garcia, Laura Martín, Lucas Mangues, Ramon Ferrer-Miralles, Neus Vázquez, Esther Villaverde, Antonio |
author_facet | Sanchez-Garcia, Laura Martín, Lucas Mangues, Ramon Ferrer-Miralles, Neus Vázquez, Esther Villaverde, Antonio |
author_sort | Sanchez-Garcia, Laura |
collection | PubMed |
description | Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment. |
format | Online Article Text |
id | pubmed-4748523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47485232016-02-11 Recombinant pharmaceuticals from microbial cells: a 2015 update Sanchez-Garcia, Laura Martín, Lucas Mangues, Ramon Ferrer-Miralles, Neus Vázquez, Esther Villaverde, Antonio Microb Cell Fact Review Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment. BioMed Central 2016-02-09 /pmc/articles/PMC4748523/ /pubmed/26861699 http://dx.doi.org/10.1186/s12934-016-0437-3 Text en © Sanchez-Garcia et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Sanchez-Garcia, Laura Martín, Lucas Mangues, Ramon Ferrer-Miralles, Neus Vázquez, Esther Villaverde, Antonio Recombinant pharmaceuticals from microbial cells: a 2015 update |
title | Recombinant pharmaceuticals from microbial cells: a 2015 update |
title_full | Recombinant pharmaceuticals from microbial cells: a 2015 update |
title_fullStr | Recombinant pharmaceuticals from microbial cells: a 2015 update |
title_full_unstemmed | Recombinant pharmaceuticals from microbial cells: a 2015 update |
title_short | Recombinant pharmaceuticals from microbial cells: a 2015 update |
title_sort | recombinant pharmaceuticals from microbial cells: a 2015 update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748523/ https://www.ncbi.nlm.nih.gov/pubmed/26861699 http://dx.doi.org/10.1186/s12934-016-0437-3 |
work_keys_str_mv | AT sanchezgarcialaura recombinantpharmaceuticalsfrommicrobialcellsa2015update AT martinlucas recombinantpharmaceuticalsfrommicrobialcellsa2015update AT manguesramon recombinantpharmaceuticalsfrommicrobialcellsa2015update AT ferrermirallesneus recombinantpharmaceuticalsfrommicrobialcellsa2015update AT vazquezesther recombinantpharmaceuticalsfrommicrobialcellsa2015update AT villaverdeantonio recombinantpharmaceuticalsfrommicrobialcellsa2015update |